Issue 2, 2024

Advances of cassava starch-based composites in novel and conventional drug delivery systems: a state-of-the-art review

Abstract

Starch has emerged as a new attractive biopolymer for use in pharmaceutical applications, owing to its distinctive physical, chemical and functional properties. This biopolymer has several potential advantages: it is biocompatible, low cost, non-toxic and easily isolated from plant sources. In the pharmaceutical field, starch is used as a raw material for developing various drug delivery platforms. Generally, cassava starch (tapioca) is obtained from the swollen roots of the perennial shrub Manihot esculenta and it contains a low amount of amylose in contrast to other varieties of starches. Because of this reason, cassava starch exhibits various prime benefits, including a low gelatinization temperature, higher swelling power and a relatively high viscosity paste, making it a preferable excipient for pharmaceutical applications. However, cassava starches in their native form are not effective for many applications because of their inefficiency in handling various processing requirements like high temperature and diverse pH. Their applicability can be enhanced by starch modification. These functional starches have demonstrated outstanding prospects as primary excipients in many pharmaceutical formulations. In this article, we discuss the potential application of cassava starches in the pharmaceutical and biomedical fields, along with the toxicity assessment of modified cassava starches.

Graphical abstract: Advances of cassava starch-based composites in novel and conventional drug delivery systems: a state-of-the-art review

Article information

Article type
Review Article
Submitted
07 Oct 2023
Accepted
04 Mar 2024
First published
27 Mar 2024
This article is Open Access
Creative Commons BY license

RSC Pharm., 2024,1, 182-203

Advances of cassava starch-based composites in novel and conventional drug delivery systems: a state-of-the-art review

S. Das, M. K. Das, T. Jamatia, B. Bhattacharya, R. Mazumder, P. K. Yadav, N. R. Ghose Bishwas, T. Deka, D. Roy, B. Sinha, B. Das, I. Daule, K. Paul, A. Roy, A. Choudhury, P. Sadhukhan, D. Sarmah, D. Bhargab, B. K. Jana, D. Tayeng, N. Guha, B. Kalita and S. Mandal, RSC Pharm., 2024, 1, 182 DOI: 10.1039/D3PM00008G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements